Significant changes in diet, environment, and population increase gastrointestinal cancer morbidity. A growing number of novel biomarkers and underlying mechanisms are being elucidated, some of which may even conflict with assumptions of past decades. Therefore, collecting recent findings on novel diagnostic/prognostic factors, biomarkers, and/or risk factors in gastrointestinal cancers is a prerequisite for a better understanding of the disease. Despite remarkable progressions in surgical treatments and chemotherapies, the prognosis of gastrointestinal cancer is far from satisfactory due to the high occurrence of drug resistance. Based on the identification of novel biomarkers as well as their underlying mechanisms, targeted drug development will provide significant complementary therapeutic effects to conventional chemoradiotherapies. High-throughput methods such as next-generation sequencing on RNA level and mass spectrometry on protein/lipid/metabolite level serve as efficient strategies for biomarker identification and drug development. This Research Topic aims at presenting recent advances on gastrointestinal cancer biomarkers and their underlying functional mechanisms, providing a better understanding of carcinogenesis, tumor progression, tumor relapse, as well as drug resistance. This will subsequently contribute to the development of novel therapeutic interventions targeting gastrointestinal cancers, thus improving patients' outcomes.
We welcome submissions covering, but not limited to, the following aspects:
1. Novel diagnostic/prognostic factors, biomarkers, and/or risk factors in gastrointestinal cancers
2. Therapeutic evaluation of new pharmacological inhibitors or specific mAb drugs targeting gastrointestinal cancers, including drug combination, drug resensitization, etc.
3. Improved high-throughput approaches, such as mass spectrometry and next-generation sequencing, may help to systematically screen for molecular alterations or elucidate therapeutic mechanisms in gastrointestinal cancer
4. High-quality clinical studies, such as cohort studies or RCT, provide evidence for the clinical application of diagnostic/prognostic factors or therapies in gastrointestinal cancers
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Significant changes in diet, environment, and population increase gastrointestinal cancer morbidity. A growing number of novel biomarkers and underlying mechanisms are being elucidated, some of which may even conflict with assumptions of past decades. Therefore, collecting recent findings on novel diagnostic/prognostic factors, biomarkers, and/or risk factors in gastrointestinal cancers is a prerequisite for a better understanding of the disease. Despite remarkable progressions in surgical treatments and chemotherapies, the prognosis of gastrointestinal cancer is far from satisfactory due to the high occurrence of drug resistance. Based on the identification of novel biomarkers as well as their underlying mechanisms, targeted drug development will provide significant complementary therapeutic effects to conventional chemoradiotherapies. High-throughput methods such as next-generation sequencing on RNA level and mass spectrometry on protein/lipid/metabolite level serve as efficient strategies for biomarker identification and drug development. This Research Topic aims at presenting recent advances on gastrointestinal cancer biomarkers and their underlying functional mechanisms, providing a better understanding of carcinogenesis, tumor progression, tumor relapse, as well as drug resistance. This will subsequently contribute to the development of novel therapeutic interventions targeting gastrointestinal cancers, thus improving patients' outcomes.
We welcome submissions covering, but not limited to, the following aspects:
1. Novel diagnostic/prognostic factors, biomarkers, and/or risk factors in gastrointestinal cancers
2. Therapeutic evaluation of new pharmacological inhibitors or specific mAb drugs targeting gastrointestinal cancers, including drug combination, drug resensitization, etc.
3. Improved high-throughput approaches, such as mass spectrometry and next-generation sequencing, may help to systematically screen for molecular alterations or elucidate therapeutic mechanisms in gastrointestinal cancer
4. High-quality clinical studies, such as cohort studies or RCT, provide evidence for the clinical application of diagnostic/prognostic factors or therapies in gastrointestinal cancers
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
